NeuroMetrix, Inc. (Nasdaq: NURO) is showing  Quell®, its 100% drug-free Wearable Pain Relief Technology™ to sleep medicine professionals from around the world at SLEEP 2017, the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) June 5-7, 2017 in Boston, MA. SLEEP 2017 is the largest scientific meeting dedicated exclusively to sleep medicine and sleep research.

Experts recommend that adults get between seven and nine hours of sleep each night to function at their best, but up to two-thirds of those with chronic pain conditions experience some form of sleeping disorder, such as insomnia. Inadequate sleep often worsens pain symptoms, which can precipitate a vicious cycle of decreased activity during the day and even less sleep at night. NeuroMetrix is uniquely positioned to address the impact of chronic pain on sleep with Quell, the only transcutaneous electrical nerve stimulator cleared by the FDA for use during sleep that is available over the counter.

"Chronic pain can be extremely disruptive to one's quality of life," said Shai N. Gozani, M.D., Ph.D. "Many people find that their pain tends to increase throughout the day and peak at night. Unfortunately, those higher levels of pain can prevent them from getting to sleep and staying asleep. We're pleased to have an opportunity to show sleep medicine professionals a drug-free pain relief option they can share with their patients."

Quell measures and tracks sleep data to help users understand the amount and quality of their sleep. Quell also analyzes body movements and position while users are sleeping. These measurements are available via the Quell Relief app.

SLEEP 2017 is being held at the Hynes Convention Center in Boston, MA. Attendees can learn more about Quell by visiting booth #2210 during the conference and by following along on Twitter  @Quellrelief.

About Quell

Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit  QuellRelief.com for more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck ®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit  www.NeuroMetrix.com.

If you liked this article you might like

The 7 Most Intriguing Products We Saw at CES

NeuroMetrix (NURO) Stock Gains After Launching Diabetes Test in Mexico

Insider Trading Alert - CMPR, AER And NURO Traded By Insiders

Insider Trading Alert - SKT, HEB And NURO Traded By Insiders

5 Breakout Stocks Under $10 Set to Soar